(Celecoxib + ciprofloxacin) is under clinical development by NeuroSense Therapeutics and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Celecoxib + ciprofloxacin)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Celecoxib + ciprofloxacin) overview
PrimeC is a fixed dose combination drug of celecoxib and ciprofloxacin. The therapeutic candidate is under development for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease . It is an extended release formulation administered through oral route in the form of capsule. It acts by targeting DICER gene and COX -2.
NeuroSense Therapeutics overview
NeuroSense Therapeutics is a biopharmaceutical company that discovers and develops novel therapeutics for the treatment of neurodegenerative diseases. The company is investigating PrimeC, a novel formulation composed of ciprofloxacin and celecoxib to treat amyotrophic lateral sclerosis (ALS). It is also developing novel therapeutics for alzheimer’s and parkinson’s diseases. NeuroSense Therapeutics conducts research and study mechanisms in targeting neurodegenerative diseases. The company has an operational presence in the US. NeuroSense Therapeutics is headquartered in Herzliya, Israel.
For a complete picture of (Celecoxib + ciprofloxacin)’s drug-specific PTSR and LoA scores, buy the report here.